300653 Yantai Zhenghai Bio-Tech
- 20.70
- -0.35-1.66%
Yantai Zhenghai Bio-Tech News
Yantai Zhenghai Bio-Tech (300653.SZ): During the use of active biological bone, doctors decide on the selection of internal fixation devices based on clinical needs. Currently, no related supporting medical devices are provided.
Zhenghai Bio-tech (300653.SZ) stated on the investor interaction platform that the company's active biological bone product is mainly used to fill bone defects caused by trauma or surgery that do not affect the stability of bone structure. During the use of active biological bone, doctors determine the choice of internal fixation devices according to clinical needs, and the company currently does not provide relevant supporting medical devices. Umbilical cord mesenchymal stem cells are currently in the product process validation stage. The company will continue to cultivate in the field of regenerative medicine, actively researching and developing products and technologies including signal molecules, seed cells, additive manufacturing, genetic engineering, and synthetic biology to create medical devices and treatments.
Yantai Zhenghai Bio-Tech (300653.SZ) equity distribution in 2023: 8.01804 yuan per 10 shares.
Zhenghai Bio-Tech (300653.SZ) announced its annual equity distribution plan for 2023: based on the company's existing total share capital after deducting the repurchased shares, it will distribute RMB 8.01804 in cash per 10 shares to all shareholders. The equity distribution share registration date is June 13, 2024, and the ex-rights and ex-dividend date is June 14, 2024.
Yantai Zhenghai Bio-tech (300653.SZ) has repurchased 0.1679% of its shares, at a cumulative cost of 7.1857 million yuan.
On June 5th, Gelunhui reported that Yantai Zhenghai Bio-Tech (300653.SZ) announced that as of May 31, 2024, the company repurchased 302,300 shares of the company's stock through a share repurchase special securities account through centralized bidding trading, accounting for 0.1679% of the company's total share capital, with a highest transaction price of 24.83 yuan/share, a lowest transaction price of 22.90 yuan/share, and a total amount paid of 7,185,656.74 yuan (excluding transaction fees). This buyback complies with the company's share repurchase plan and relevant laws and regulations.
Express News | Zhenghai Biotech: Oral Repair Mask Receives Continued Registration
Zhenghai Biology (300653.SZ): The company's active biological bone products were officially marketed in early 2024
Gelonghui, May 15, 丨 Zhenghai Biotech (300653.SZ) was surveyed by specific subjects and said that the company's active biological bone products were officially marketed in early 2024. In the first quarter, it mainly completed online connections in more than 2/3 provinces across the country and admissions work in some hospitals. In the second quarter, it will continue to steadily expand the scope of admission, and sales of related products will gradually increase.
Express News | Zhenghai Biology: The production and preparation process of rhBMP-2, an active factor specifically bound in active biological bone in the marketed product is a synthetic biological technology
Express News | Zhenghai Biotech: Sales of active biological bone products will gradually increase after the second quarter
Zhenghai Biotech (300653): 1Q consumer medical demand still hasn't recovered, waiting for flowers to blossom
1Q24 is pressured by short-term performance growth due to fluctuations in downstream demand. I am optimistic about the subsequent recovery of the company's 1Q24 operating income/net profit attributable to mother/net profit of 0.90/0.40/0.35 billion yuan, compared to -18% /-24
Express News | Zhenghai Biotech: Appoints Song Kan as the company's general manager
Express News | Zhenghai Biotech: Net profit of 40.3815 million yuan in the first quarter decreased 24.38% year-on-year
Zhenghai Biology (300653): Short-term performance, active biological bone under pressure will soon be released
Incident: The company announced its 2023 annual report. In 2023, it achieved revenue of 414 million yuan, a year-on-year decrease of 4.52%; realized net profit of 191 million yuan, an increase of 2.98% over the previous year. Company Announcement 2024
Express News | Zhenghai Biotech: A clinical trial summary meeting on calcium-silicon bioceramic bone repair materials was successfully held
Express News | Zhenghai Biotech: The company's oral repair film products have not yet been collected
Zhenghai Biotech (300653.SZ): Initial repurchase of 17,500 shares involving 4181,000 yuan
Gelonghui, April 3, 丨 Zhenghai Biotech (300653.SZ) announced that on April 3, 2024, the company used its own funds to repurchase shares through centralized bidding transactions for the first time through a special stock repurchase securities account. The number of shares repurchased was 17,500 shares, accounting for 0.01% of the company's current total share capital. The highest transaction price of the repurchase was 23.98 yuan/share, and the minimum transaction price was 23.82 yuan/share. The total transaction amount was 4181.37 million yuan (excluding transaction fees).
Zhenghai Biotech (300653): Performance is in line with expectations, core products maintain market leadership
The 2023 results are basically in line with our expectations. The company announced the 2023 results: revenue of 414 million yuan, a year-on-year decrease of 4.52%; net profit to mother was 191 million yuan, an increase of 2.98% year-on-year, corresponding to a profit of 1.06 million yuan per share
Express News | Zhenghai Biotech: The company's light-curing composite resin obtained a medical device registration certificate
Zhenghai Biology (300653.SZ): The main products in the dental department are oral repair membranes and bone repair materials. Currently, the two products are not involved in collection
Gelonghui April 2 丨 Zhenghai Biotech (300653.SZ) was surveyed by specific subjects on April 1, 2024, on “Will oral membrane powder products be collected?” The company replied that the company's main products in the dental department are oral repair membranes and bone repair materials. Currently, the two products are not involved in collection. Product collection is affected by many factors, and the company will pay close attention to the promotion and implementation of relevant collection policies.
Zhenghai Biotech (300653.SZ): Active biological bone products have completed the conversion verification process within 2023 and officially launched for sale
Gelonghui April 2 丨 Zhenghai Biotech (300653.SZ) was surveyed by specific subjects on April 1, 2024, on “Sales progress of active biological bone products?” The company replied that according to the “National Organization's Centralized Volume Procurement Notice for Artificial Crystals and Sports Medicine Medical Consumables (No. 2)” issued by the Tianjin Pharmaceutical Procurement Center in September 2023, the company's product active biological bone is not within the scope of this collection. The company's active biological bone products have completed the conversion verification process within 2023 and are officially marketed. Up to now, the Internet connection work has been completed in more than 2/3 provinces, related markets
Zhenghai Biotech: Active biological bone conversion is nearing completion in the second half of the year, and marketing is imminent
Gelonghui April 2 | Zhenghai Biotech's April 1 online conference said that in 2023, active biological bone is mainly being verified for conversion, and the company has been keeping a close eye on changes in collection policies. Active biological bone production is nearing its end in the second half of the year, and the launch is imminent. The company has also formulated more targeted pricing and sales strategies in accordance with the policy. In the future, the company will also continue to track policy developments such as bidding and price limits that may be carried out in various regions.
Zhenghai Biotech (300653) Annual Results Review: Stable fundamentals, optimistic about commercialization progress of active bone in 24 years
Incident: The company released its annual results report for 23 years, achieved revenue of 414 million yuan (-4.5%) for the whole year, achieved net profit of 191 million yuan (+3.0%) attributable to shareholders of listed companies, and realized the deduction of non-recurring profit and loss
Analysis
Price Target
No Data
